AMB-CHMINACA

AMB-CHMINACA.svg

{{Drugbox | verifiedrevid = 477318752 | IUPAC_name = N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester | image = AMB-CHMINACA_structure.png | width = 200 | legal_CA = Schedule II | legal_UK = Class B | legal_US = Schedule I | CAS_number = 1185887-21-1 | PubChem = 71787280 | ChemSpiderID = 29342035 | UNII = | KEGG = | ChEMBL = | C=23 | H=32 | N=2 | O=3 | smiles = O=C(N[C@@H](C(OC)=O)C(C)C)c1nn(CC2CCCCC2)c3c1cccc3 | StdInChI = 1S/C23H32N2O3/c1-15(2)21(23(27)28-3)24-22(26)20-18-10-6-7-11-19(18)25-17(20)14-16-12-8-4-5-9-13-16/h6-7,10-11,15-17H,4-5,8-9,12-14H2,1-3H3,(H,24,26)/t17-/m0/s1 | StdInChIKey = }}

AMB-CHMINACA is a synthetic cannabinoid that has been used as a designer drug. It is a potent agonist of the CB1 receptor and CB2 receptor, which are part of the endocannabinoid system.

Chemical Structure

AMB-CHMINACA is chemically classified as an indazole-based synthetic cannabinoid. Its full chemical name is N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester. The structure includes a cyclohexylmethyl group attached to the indazole core, which is linked to a valine methyl ester.

Pharmacology

AMB-CHMINACA acts as a potent agonist at the CB1 receptor and CB2 receptor, which are G-protein coupled receptors in the endocannabinoid system. These receptors are involved in a variety of physiological processes including pain sensation, appetite, and mood regulation.

Legal Status

In many countries, AMB-CHMINACA is classified as a controlled substance. For example, it is listed as a Schedule I substance in the United States, indicating that it is considered to have a high potential for abuse and no accepted medical use. In the United Kingdom, it is classified as a Class B drug under the Misuse of Drugs Act 1971.

Health Effects

The use of AMB-CHMINACA has been associated with a range of adverse health effects. These can include tachycardia, hypertension, nausea, vomiting, hallucinations, and seizures. Due to its potency and the variability in the composition of synthetic cannabinoid products, the risk of overdose and severe adverse effects is significant.

See Also

• Synthetic cannabinoids
• Endocannabinoid system
• CB1 receptor
• CB2 receptor
• Designer drugs

References

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian